^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    lifastuzumab vedotin (DNIB0600A)

    i
    Company:
    Roche
    Drug class:
    Microtubule inhibitor, NaPi2b-targeted antibody-drug conjugate
    Related drugs:
    Apply
    A Study to Evaluate the Safety and Pharmacology of DNIB0600A in Participants With Platinum-Sensitive Ovarian Cancer or Non-Squamous Non-small Cell Lung Cancer (NCT01995188)
    Phase 1
    Genentech, Inc.
    Completed
    Last update posted :
    10/04/2017
    Initiation :
    12/16/2013
    Primary completion :
    11/09/2016
    Completion :
    11/09/2016
    EGFR • ALK • SLC34A2
    |
    EGFR mutation • ALK rearrangement
    |
    Avastin (bevacizumab) • carboplatin • lifastuzumab vedotin (DNIB0600A)